Phase 1

Oxford Vacmedix announce results of successful Phase 1 trial of OVM-200

The OVM-200 Phase 1 trial has met both primary and secondary endpoints and additionally early observations of clinical efficacy have been seen. Oxford, UK – 21st April 2026 Press Release – OVM-200 Phase 1 trial Oxford Vacmedix (OVM), the UK biotech company developing novel immunotherapies to treat cancer, is delighted to announce the successful completion of the Phase 1 trial of OVM-200. The primary endpoint for safety has been met as well as the secondary endpoints for immune response a...
Read More
en_GBEnglish